Please use this identifier to cite or link to this item:
Title: Multiple Signalling Transduction Mechanisms Differentially Coupled to Somatostatin Receptor Subtypes: a Current View.
Authors: Cervia, Davide
Nunn, Caroline
Bagnoli, Paola
Keywords: Endogenous receptor;Recombinant system;G-protein;Cyclic nucleotide;Enzyme;Nitric oxide;Phospatase;Kinase
Issue Date: 2005
Publisher: Bentham Science Publishers
Source: Cervia, D., Nunn, C., Bagnoli, P. 2005. Multiple Signalling Transduction Mechanisms Differentially Coupled to Somatostatin Receptor Subtypes: a Current View. "Current Enzyme Inhibition" 1(3): 265-279
Somatostatin (SRIF) is a cyclic peptide widely distributed throughout the body with important physiological effects (mostly inhibitory) on several organ systems. SRIF may act as a neurohormone, neurotransmitter, neuromodulator or as a local factor, and exhibits potent antiproliferative activity. SRIF effects have formed the basis for the clinical use of SRIF analogues in the treatment of endocrine tumours, acromegaly and gastrointestinal disorders. Several data suggest that SRIF may also be a therapeutic target in a number of different diseases.
The binding of SRIF to its five G-protein coupled receptors leads to modulation of multiple transduction pathways, including adenylyl cyclase, guanylyl cyclase, phospholipase C, K+ and Ca2+ channels, phospholipase A2, nitric oxide, Na+/H+ exchanger, protein phosphatases and MAP kinases. The diversity of the transduction pathways reflects the pleiotropic actions of SRIF. However, our current understanding depicts a rather complicated picture and conflicting results have also been reported. Data are mostly based on in vitro experiments, and parallels with the real in vivo conditions are not so obvious. Due to the clinical relevance of the SRIF system, the elucidation of the intracellular role of endogenous SRIF receptors may offer new therapeutic perspectives. These will enable development of specific pharmacological signalling modulators which can be incorporated into the therapeutic arsenal.
The present review represents a detailed and exhaustive summary which covers the latest advances in the transduction pathways of SRIF receptors.
L'articolo è disponibile sul sito dell'editore
ISSN: 1573-4080
Appears in Collections:DISA - Archivio della produzione scientifica

Files in This Item:
File Description SizeFormat
Cervia et al-CEI 2005 1.pdf16.09 kBAdobe PDFView/Open
Show full item record

Page view(s)

Last Week
Last month
checked on Oct 23, 2020


checked on Oct 23, 2020

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.